Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)

Exclusion Criteria14

• A previous WHO grade 2, 3 or 4 bleeding event within the past year
• A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis
• A current provoked thrombotic event (e.g. catheter-related thrombosis) within last month and/or still requiring anticoagulant treatment.
• A requirement for therapeutic anticoagulant or anti-platelet drugs during ASCT
• Active angina (chest pain of presumed cardiac origin either at rest or with activity)
• Current or previous (within 2 weeks) urinary tract bleeding
• An inherited hemostatic or thrombotic disorder
• Coagulopathy defined as a prothrombin time '/International Normalization Ratio (INR) or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L
• Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies (Refractoriness is defined as 2 consecutive ABO matched platelet transfusions with platelet increment of < 7.5 and the presence of anti-HLA antibodies)
• Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL/min/1.78m2)
• Pregnant or breast-feeding
• Unwilling or unable to provide informed consent
• Participant has acquired disturbances to his/her colour vision (does not apply to congenital colour blindness)
• Participant has known sensitivity or allergy to Tranexamic Acid or any of its ingredients